Physician profile
Barbara E Amsler
NPI 1356351258
$2,030.02
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,015 · 2020: $1,015.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $278.09 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $276.96 | 2019-2020 | |
| Novo Nordisk INC | $258.77 | 2019-2020 | |
| Amgen INC. | $244.77 | 2019-2020 | |
| Amarin Pharma, INC. | $175.03 | 2019-2020 | |
| Pfizer INC. | $157.15 | 2019-2020 | |
| Astellas Pharma US INC | $95.83 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $79.86 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $79.48 | 2019-2020 | |
| Abbvie INC. | $77.05 | 2019-2020 | |
| Allergan, INC. | $49.38 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $48.41 | 2019 | |
| Sunovion Pharmaceuticals INC. | $45.49 | 2020 | |
| Lilly USA, LLC | $40.54 | 2019-2020 | |
| Zyla Life Sciences, INC. | $30.05 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $25.88 | 2019 | |
| Genentech USA, INC. | $19.59 | 2019 | |
| Assertio Therapeutics, INC. | $18.84 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $15.32 | 2020 | |
| Novartis Pharmaceuticals Corporation | $13.53 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Amsler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.